TDHL
Based on 1 Customer Validation
TDHL (Tergurid) is a dopamine receptor agonist with a Kd of 0.39 nM for D2 receptor and an orally available 5-HT-2 receptor antagonist.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 37686-84-3
- Formula: C20H28N4O
- Molecular Weight:340.46
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Proliferation and migration of cultured primary human pulmonary artery smooth muscle cells (PASMC) were dose-dependently blocked by TDHL[1].Terguride is found to bind selectively to the pituitary dopamine D2-receptors with a high affinity (Kd=0.39 nM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 37686-84-3
-
Appearance Solid
-
Molecular Weight 340.46
-
Formula C20H28N4O
-
Color White to off-white
-
SMILES
CN1[C@@]2([H])[C@@](C[C@@H](C1)NC(N(CC)CC)=O)([H])C3=CC=CC4=C3C(C2)=CN4
-
Synonyms
Tergurid; Terguride; trans-Dihydrolisuride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocol
Freshly isolated human PASMCs are treated with TDHL or vehicle for 24 h. Then, [3H]thymidine is added to each well for 6 h. After ishing with PBS, cells are lysed in 0.5 M NaOH and [3H]thymidine incorporation is quantified[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats[1]
Adult male Sprague Dawley rats (body weight 300–350 g) are used. For chronic treatment studies, seven groups with MCT-induced PH are studied. Rats are treated with TDHL (0.4, 1.2 mg/kg) for 0-28 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kekewska A, et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells. J Pharmacol Exp Ther. 2012 Feb;340(2):369-76. [Content Brief]
[2]. Mizokawa T, et al. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine. Jpn J Pharmacol. 1993 Nov;63(3):269-78. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz